New male breast enlargement may warrant testosterone, estradiol, LH, FSH and hCG testing; prolactin, SHBG and thyroid tests depend on clinical findings. Examination and medication review come first, because hormone results cannot rule out a concerning breast or testicular change.
Helstu niðurstöður
- Core hormone tests may include testosterone, estradiol, LH, FSH and quantitative hCG when examination confirms unexplained glandular enlargement.
- Morgun-testósterón should usually be collected around 7–10 am; diagnosing testosterone deficiency requires compatible symptoms and consistently low results on 2 separate mornings.
- Estradíól commonly has an adult male reference interval around 10–40 pg/mL, but the laboratory method matters and no single cutoff diagnoses gynecomastia.
- Viðbótarprófanir may include SHBG, prolactin, TSH, AFP and liver or kidney tests; a broad panel is not automatically necessary for every adolescent.
- Chest examination distinguishes a firm or rubbery subareolar disc from diffuse fat, although glandular tissue and fat can coexist.
- Yfirferð lyfja should include prescribed drugs, testosterone, anabolic steroids and supplements; do not stop essential treatment without advice.
- Pubertal enlargement often settles within approximately 1–2 years, but prepubertal onset, rapid progression or persistence beyond the expected course warrants reassessment.
- Skjót mat is needed for a hard off-centre lump, nipple retraction or discharge, enlarged armpit nodes, or a new testicular lump; sudden severe testicular pain is an emergency.
Which hormones belong in a gynecomastia blood test?
A gynecomastia blood test may include total testosterone, estradiol, LH, FSH and quantitative hCG for unexplained glandular enlargement. SHBG, prolactin, TSH and other investigations depend on the examination, symptoms and medication history—not everyone needs the same panel.
The European Academy of Andrology guideline describes a potentially broad investigation set, including testosterone, estradiol, SHBG, LH, FSH, TSH, prolactin, hCG, AFP, liver and renal function (Kanakis et al., 2019). That is a framework for evaluating the cause, not a recommendation to purchase every assay without assessment; typical pubertal enlargement and new unexplained adult enlargement have different starting probabilities.
Testing answers 3 different questions: whether androgen activity is reduced, whether estrogen stimulation is increased, and whether a systemic illness or hormone-producing growth needs investigation. A normal estradiol result does not eliminate the first possibility, and normal testosterone does not exclude medication-related effects at the breast tissue receptor.
Kantesti er AI blóðprufugreiningartæki that can help explain how these hormone results relate to one another, including why 2 testosterone measurements may be needed. Our hormone biomarker reference guide provides additional laboratory context, but neither our interpretation nor a normal panel replaces examination of a new lump.
How does examination distinguish gynecomastia from chest fat?
Brjóstastækkun hjá körlum (gynecomastia) is enlargement of glandular breast tissue, usually felt as a rubbery or firm disc centred beneath the nipple. Pseudogynecomastia is predominantly diffuse fat; the 2 can coexist, so appearance or body weight alone cannot establish the diagnosis.
A clinician assesses the location, consistency, mobility and symmetry of the tissue, then checks the nipples and armpit nodes. For example, a hypothetical 2 cm mobile, tender subareolar disc has a different examination pattern from a 2 cm hard lump away from the nipple; size alone does not distinguish benign enlargement from cancer.
Recent glandular proliferation can be tender, whereas longstanding tissue may become firmer as fibrosis develops over months. Tenderness is therefore a clue about timing, not proof of a harmless cause; a painful lump with skin changes or rapid progression still deserves assessment, even when symptoms have lasted only 2 weeks.
Weight loss may reduce the fatty component without removing an established glandular disc, and a person can have true gynecomastia at a normal BMI. Our discussion of weight-related testing decisions explains why endocrine investigations should follow clinical clues rather than an assumption that every persistent chest change is caused by excess weight.
When does new male breast enlargement warrant hormone testing?
New unexplained adult gynecomastia, prepubertal enlargement, rapid progression or accompanying endocrine symptoms warrant clinical assessment and often targeted testing. Typical pubertal gynecomastia may instead be monitored, because it commonly improves over approximately 1–2 years without a persistent hormonal disorder.
A reassuring adolescent pattern consists of subareolar tissue arising during otherwise normal puberty, without a suspicious lump, systemic illness or abnormal genital examination. Persistence for more than about 2 ára, substantial distress or continued growth merits reassessment; that interval is a practical review point, not a rule that earlier investigation is unnecessary.
Prepubertal glandular enlargement is unusual and should not be dismissed as ordinary puberty. Clinicians look for hormone exposure, unusual pubertal development and other endocrine signs; our guide to early puberty hormone testing explains why age, growth velocity and developmental stage change the meaning of an LH or testosterone result.
In an adult, reduced libido, erectile difficulties, infertility, small testes, weight loss, tremor or features of liver disease make laboratory testing more informative. The 2019 EAA guideline also advises looking for underlying disease even when a medication seems plausible, because a drug explanation and a second medical cause can occur together (Kanakis et al., 2019).
Why does medication review matter before hormone testing?
Medication-related gynecomastia may arise from reduced androgen action, altered hormone production or increased estrogen exposure. A useful review includes prescription drugs, nonprescription products and anabolic steroids, with doses and start dates; even a plausible drug cause does not cancel the need to examine a new lump.
Spironolactone, antiandrogens, finasteride, some antipsychotics and certain HIV treatments are recognised possibilities, although the strength of evidence differs between drugs. Finasteride is used at 1 mg or 5 mg daily for different indications; those doses belong in the history, but neither dose establishes causation or predicts whether an individual will develop enlargement.
Testosterone can be converted to estradiol, while stopping anabolic steroids may leave endogenous testosterone production suppressed. A hypothetical person developing tenderness 6 vikur after changing a testosterone regimen needs review of formulation, dose and sampling time—not an automatic aromatase inhibitor; our estradiol review during TRT explains why symptoms and numbers can disagree.
Supplements marketed as testosterone boosters may contain undeclared hormonal ingredients, so bring photographs of the packaging and a complete ingredient list. A practical history covers at least the preceding 3–6 mánuðir, including stopped products; our áhrifum lyfja á eldri fullorðna also addresses why prescribed treatment should be adjusted with the prescriber rather than stopped independently.
How should testosterone be checked and interpreted?
Heildar-testósterón should usually be measured fasting in the morning, often around 7–10 am, when investigating possible deficiency. A low result requires confirmation on a separate morning, and diagnosis depends on compatible symptoms rather than breast enlargement or a single laboratory flag alone.
The Endocrine Society guideline gives a harmonised total testosterone reference interval of 264–916 ng/dL, um það bil 9.2–31.8 nmol/L, for healthy, nonobese men aged 19–39 when appropriately standardised assays are used (Bhasin et al., 2018). The lower boundary is population- and method-specific; it is not a universal diagnosis threshold for every age group, laboratory or clinical situation.
lágt eða hátt SHBG can make total testosterone misleading, so clinicians may request calculated free testosterone using total testosterone, SHBG and albumin, or equilibrium dialysis where available. Direct analogue free-testosterone immunoassays are less reliable; our low free testosterone explanation shows why a value such as 280 ng/dL needs its binding-protein context.
Kantesti AI can help organise 2 separate testosterone results, their collection times and the accompanying LH values, but it cannot diagnose hypogonadism from a screenshot alone. Shift workers may need sampling aligned with their main sleep period rather than a rigid clock time; our sýnatöku á hormónum að morgni explains how sleep and recent illness affect preparation.
What do gynecomastia estradiol levels actually show?
Gynecomastia estradiol levels may be normal or elevated, because glandular growth reflects estrogen action relative to androgen action at the tissue. Many laboratories use an adult male estradiol interval around 10–40 pg/mL, but the assay-specific range—not an internet cutoff—should guide interpretation.
An estradiol interval of 10–40 pg/mL samsvarar um það bil 37–147 pmól/L; converting units prevents the same result from appearing nearly 4 times higher on a different report. Some laboratories have wider intervals, and immunoassays can be less accurate at the low concentrations typical in men, so unexpected results may need confirmation with a suitably validated LC–MS/MS method.
A hypothetical estradiol result of 48 pg/mL with a laboratory upper limit of 40 is a mild elevation, not evidence by itself of a hormone-producing growth. The next questions are whether testosterone treatment, increased aromatisation, liver dysfunction or assay interference could explain it; rapid enlargement, substantially abnormal results or a testicular finding changes the urgency.
Það er no validated universal estradiol-to-testosterone ratio that diagnoses gynecomastia, particularly when the hormones are reported in different units. SHBG also changes free hormone availability, which is why our SHBG og testósterón leiðarvísir is relevant; lowering estradiol solely to place a number below 40 pg/mL can create problems for bone and sexual health.
| Styrkur | Bil | Merking |
|---|---|---|
| Illustrative adult male interval | 10–40 pg/mL; approximately 37–147 pmol/L | Common laboratory interval, not universal; normal estradiol does not exclude gynecomastia. |
| Above the laboratory upper limit | For example, 48 pg/mL when the upper limit is 40 | Review medications, testosterone exposure and assay accuracy before drawing conclusions. |
| Clearly elevated and unexplained | No universal numerical threshold | Clinical findings determine confirmation, endocrine referral and investigation for a hormone-producing source. |
What do LH and FSH reveal about the underlying cause?
Lágt testósterón með háu LH suggests primary testicular dysfunction, while low testosterone with low or inappropriately normal LH suggests a hypothalamic–pituitary or functional cause. FSH adds information about sperm-producing function; interpreting all 3 hormones together is more useful than reading isolated reference-range flags.
Illustrative adult male intervals are LH 1.7–8.6 IU/L og FSH 1.5–12.4 IU/L, but age, assay and laboratory affect the limits. An LH of 4 IU/L may be normal when testosterone is normal yet inappropriately normal when testosterone is repeatedly very low, because the expected compensatory response is an increase in LH.
Small, firm testes, infertility and a high-gonadotropin pattern may prompt consideration of Klinefelter-heilkenni, usually associated with a 47,XXY karyotype. Chromosome testing is not required for every person with gynecomastia; our Klinefelter chromosome testing guide explains why physical findings and reproductive history determine whether it belongs in the workup.
Low testosterone with suppressed LH and FSH may also follow anabolic steroid exposure, opioid use, severe illness or significant energy deficit. A hypothetical athlete with testosterone 190 ng/dL, LH 0.8 IU/L and recent steroid withdrawal has a different starting explanation from someone with the same testosterone and LH 18 IU/L; neither pattern justifies treatment without confirmation and assessment.
When should prolactin and macroprolactin be checked?
Prolactin testing is particularly useful when breast enlargement accompanies low testosterone with low or normal LH, reduced libido, nipple milk secretion or pituitary symptoms. Mild elevations should usually be reassessed in context; many adult male laboratory intervals have an upper limit around 15–20 ng/mL, but ranges vary.
Raised prolactin generally contributes indirectly by suppressing reproductive hormone signalling rather than acting as the usual direct driver of glandular enlargement. A hypothetical result of 28 ng/mL against an upper limit of 18 may reflect stress, medication, hypothyroidism or a persistent endocrine problem; our mild prolactin elevation guide explains why one modest result rarely settles the question.
For a repeat sample, follow the laboratory's instructions and consider a quiet rest of 20–30 minutes beforehand, particularly if the first collection was stressful. A fall from 28 til 14 ng/mL would change the interpretation, whereas a persistent elevation requires medication and thyroid review; headaches with visual changes should be assessed promptly rather than waiting for routine retesting.
Kantesti er AI blóðrannsóknartúlkunarvettvangur that can help distinguish a total prolactin flag from a report of monomeric prolactin after laboratory processing. Persistent elevation with few compatible symptoms may lead to macroprolactin testing; our macroprolactin result explanation describes why this larger, often less biologically active complex can prevent an unnecessary leap to pituitary imaging.
Why might hCG and AFP be included in the workup?
Quantitative hCG can identify a hormone signal associated with certain testicular or other growths that may cause gynecomastia; AFP provides additional information when a germ-cell process is suspected. Neither marker is a stand-alone cancer diagnosis, and normal results do not exclude a testicular mass.
Some laboratories use an adult male hCG reference limit below 2 IU/L, while others report different cutoffs, including below 5; the exact method and reference interval must be checked. A clearly unexpected result, such as 38 IU/L in a hypothetical man without prescribed hCG, warrants prompt clinician review, confirmation and investigation rather than an assumption that the assay is only relevant to pregnancy.
A small unexpected hCG elevation can occasionally reflect assay interference, including heterophile antibodies, and clinicians may use a different analytical platform or other laboratory checks. IU/L and mIU/mL are numerically equivalent for hCG, so changing between those units does not explain a discrepancy; prescribed fertility treatment or bodybuilding-related hCG use must also be disclosed.
AFP reference limits are often around 8–10 ng/mL, but liver disease can also elevate AFP and some testicular cancers do not produce it. Our AFP interpretation and limits explains this overlap; a new testicular lump requires examination and usually ultrasound even if both hCG and AFP fall within the laboratory range.
Which thyroid, liver and kidney tests may be useful?
TSH, liver function and kidney function may help identify systemic causes of gynecomastia, particularly when symptoms or examination suggest illness. Hyperthyroidism can alter SHBG and hormone balance, while liver disease or advanced kidney disease can disrupt hormone handling; a mildly abnormal result alone rarely explains new enlargement.
A common adult TSH interval is approximately 0.4–4.0 mIU/L, although laboratories differ. A suppressed TSH with elevated free T4 or T3 supports hyperthyroidism, which can raise SHBG and shift effective androgen–estrogen balance; our TSH and thyroxine explanation helps distinguish that pattern from a single borderline TSH result.
Liver assessment may include ALT, AST, bilirubin, albumin and other tests selected for the clinical situation; normal transaminases do not exclude advanced chronic liver disease. Albumin is commonly around 35–50 g/L in adults, and our leiðbeiningar um greiningu á sermisprótínum explains why binding proteins and synthetic function can matter more than a small isolated enzyme rise.
Kidney tests usually begin with creatinine and estimated GFR, interpreted alongside history rather than as a direct gynecomastia test. An eGFR of 58 ml/mín/1,73 m² on one occasion does not establish chronic kidney disease or explain breast enlargement; our cirrhosis symptom and laboratory guide also shows why systemic causes need a recognisable clinical pattern, not merely one abnormal number.
How should you prepare for gynecomastia hormone testing?
Preparation for gynecomastia hormone testing depends on the assays and any hormone treatment: morning fasting collection is usually appropriate for diagnostic testosterone, while treatment monitoring requires formulation-specific timing. Record the collection time, last dose and recent illness so 2 results can be compared meaningfully.
Poor sleep, acute illness and major calorie restriction can temporarily lower testosterone, so routine diagnostic testing is often deferred until recovery when clinically safe. If a hypothetical result of 220 ng/dL was collected after an overnight shift and fever, a properly timed repeat may be more useful than immediately labelling permanent deficiency; our leiðbeiningar um undirbúning fyrsta sýnis covers what to document.
Biotin can interfere with certain immunoassays, with the direction and magnitude depending on the assay design. Supplements containing 5–10 mg, sem samsvarar 5,000–10,000 micrograms, deserve particular attention, but there is no universal safe washout period; ask the laboratory or clinician because dose, renal function and platform determine how long withholding may be required.
When reviewing results with Kantesti AI, retain the laboratory's units, reference intervals and any sample-quality comments, together with the time since the last testosterone dose. A sample collected 24 hours after an injection is not automatically comparable with one collected immediately before the next dose; unexplained discordance may require laboratory confirmation rather than a medication change.
Which breast or testicular changes need prompt evaluation?
A hard off-centre breast lump, nipple retraction or discharge, skin distortion, enlarged armpit nodes, or a new testicular lump needs prompt clinical evaluation. Do not wait for a gynecomastia blood test to reassure you; sudden severe testicular pain requires emergency care because torsion is time-sensitive.
Gynecomastia usually produces tissue centred beneath the nipple, but unilateral enlargement can still be benign and bilateral enlargement is not a guarantee of safety. A hypothetical 1 cm hard, fixed lump away from the nipple deserves a different pathway from a soft, mobile subareolar disc; blood tests cannot reliably distinguish these conditions without examination and, when needed, imaging.
When the examination is clearly typical of gynecomastia, routine breast imaging may not be necessary; an indeterminate or suspicious finding may require ultrasound, mammography and tissue sampling according to the clinical assessment. The 2019 EAA guideline supports imaging when examination is equivocal and direct tissue assessment for suspicious findings (Kanakis et al., 2019), rather than using normal estradiol as a reason to dismiss a lump.
A painless testicular lump, new firmness, size change or heaviness also deserves prompt review, while sudden severe pain should bypass routine outpatient hormone testing. Our family cancer risk testing guide explains why symptom-directed assessment differs from screening; a person with a new mass should not wait 3–6 mánuðir for the next planned gynecomastia follow-up.
How do hormone patterns change the next step?
Hormone patterns guide the search for a cause; they do not choose treatment on their own. Low testosterone needs confirmation and clinical correlation, unexpected hCG needs prompt investigation, and an isolated mild estradiol rise may need review rather than suppression; the examination determines which pathway takes priority.
Consider a clearly hypothetical 52-year-old with tender subareolar tissue, testosterone 210 ng/dL, LH 15 IU/L, estradiol 26 pg/mL and no suspicious mass. Repeating testosterone and assessing primary testicular dysfunction is more logical than treating normal estradiol as the problem; a low androgen signal can permit glandular enlargement even when estrogen lies inside its reference interval.
A second hypothetical adult has testosterone 520 ng/dL, estradiol 48 pg/mL and enlargement beginning after a medication change, while examination is reassuring and hCG is normal. Medication review and possible estradiol confirmation may come before treatment; if the same person instead has hCG 38 IU/L or a testicular lump, the priority changes to prompt investigation regardless of testosterone.
The EAA guideline does not recommend routine use of aromatase inhibitors, selective estrogen receptor modulators or non-aromatisable androgens for gynecomastia in general (Kanakis et al., 2019), although specialists may consider selected off-label treatment in particular circumstances. Kantesti can support discussion of 2 or more related results, en validation and clinical limits explain why an AI interpretation should not initiate testosterone, tamoxifen or estrogen-lowering medication.
Follow-up, AI limitations and research publications
Follow-up should track tissue changes and the underlying cause, not repeatedly order every hormone without a reason. A clinician may use a review interval around 3–6 mánuðir for a reassuring, stable case, with earlier reassessment for progression or new breast, testicular or systemic symptoms.
A useful follow-up record includes symptom onset, medication changes, examination findings and whether a glandular disc is increasing or becoming less tender. Longstanding tissue may persist after the trigger is corrected, particularly after approximately 12 mánuði when fibrosis can limit regression; persistent discomfort or distress may justify specialist discussion even after the laboratory cause has been addressed.
Kantesti er AI-knúið blóðprófunargreiningartól that helps organise uploaded hormone reports and trends, including comparisons across 2 separate collection dates, without examining breast or testicular tissue. Kantesti LTD is the organisation behind the service, described on our company background page; okkar meginreglur um ábyrga notkun gervigreindar explain why new physical findings and urgent symptoms require human clinical assessment.
The 2 Zenodo útgáfur listed below are additional laboratory education resources covering iron studies and coagulation, not evidence sources for gynecomastia diagnosis or hormone treatment. The topic-specific recommendations in this article are supported by the 2019 EAA gynecomastia guideline og 2018 leiðbeiningar Endocrine Society um testósterón; a DOI identifies a deposited publication but does not, by itself, establish independent peer review or clinical validation.
Algengar spurningar
Hvaða blóðrannsóknir ætti karlmaður að fara í vegna brjóstastækkunar?
Mat á brjóstastækkun hjá körlum getur falið í sér mælingu á heildartestósteróni, estradíóli, LH, FSH og magnbundnu hCG, ásamt SHBG, prólaktíni, TSH, AFP og lifrar- eða nýrnaprófum sem valin eru eftir klínískum niðurstöðum. Leiðbeiningar Evrópsku andrófræðifélagsins frá 2019 lýsa víðtækum mögulegum rannsóknum, en ekki þurfa allir unglingar að gangast undir allar prófanirnar. Testósterón til greiningar er yfirleitt mælt að morgni á fastandi maga og mælingin endurtekin annan morgun ef gildið er lágt. Skoðun og yfirferð lyfjanotkunar eru nauðsynlegar þar sem blóðpróf geta ekki greint allar orsakir nýs hnúts í brjósti.
Geturðu verið með brjóstastækkun hjá körlum þrátt fyrir eðlilegt estradíól?
0 Brjóstastækkun hjá körlum getur komið fram þótt estradíól sé innan eðlilegra marka, því vöxtur kirtilvefs ræðst af virkni estrógens miðað við virkni andrógena í vefnum. Margar rannsóknarstofur nota viðmiðunarbilið 10–40 pg/mL fyrir fullorðna karlmenn, en niðurstaða innan þess bils útilokar ekki lágt testósterón, áhrif lyfja eða næmi í vefnum. Eðlileg niðurstaða fyrir estradíól getur heldur ekki útilokað hnút í brjósti sem vekur áhyggjur. Meðferðin ætti að beinast að klínísku orsökinni í stað þess að gera ráð fyrir að öll tilvik krefjist bælingar á estrógeni.
Þýðir hátt estradíólgildi að ég þurfi á arómatasahemli að halda?
Hátt estradíólgildi réttlætir ekki sjálfkrafa notkun arómatasahemla. Til dæmis er 48 pg/mL, þegar efri viðmiðunarmörk rannsóknarstofunnar eru 40 pg/mL, væg hækkun sem gæti kallað á endurskoðun lyfjameðferðar, mat á útsetningu fyrir testósteróni eða staðfestingu með viðeigandi mæliaðferð. EAA-leiðbeiningarnar frá 2019 mæla ekki með arómatasahemlum sem hefðbundinni almennri meðferð við brjóstastækkun hjá körlum. Of mikil lækkun estrógens getur haft neikvæð áhrif á beinheilsu og kynlífsstarfsemi, þannig að ákvarðanir um meðferð eiga að vera í höndum læknis.
Hvernig get ég greint hvort brjóstastækkun stafi af fitu eða brjóstakirtlastækkun?
Kvensjúkdómur lýsir sér yfirleitt sem gúmmíkenndum eða þéttum skífulaga vef undir geirvörtunni, en stækkun sem aðallega stafar af fitu er dreifðari. Hvort tveggja getur verið til staðar samtímis og ekki er hægt að flokka 2 cm hnút á öruggan hátt út frá stærð hans eða ljósmynd einni saman. Læknir skoðar staðsetningu og hreyfanleika vefsins, breytingar á geirvörtunni og eitla í handarkrika til að ákveða hvort þörf sé á myndgreiningu. Harður hnútur utan miðju, inndregin geirvarta eða útferð þarfnast skjóts mats í stað þess að sjálfsgreina brjóstafitu.
Ætti unglingur með brjóstastækkun hjá körlum að fara í hormónablóðpróf?
Unglingur með dæmigert kynþroskabrjóst og eðlilegan þroska að öðru leyti má vera undir eftirliti án víðtækrar hormónarannsóknar. Stækkun á kynþroskaskeiði gengur oftast til baka á um það bil 1–2 árum, en frekari aukning, viðvarandi einkenni umfram væntanlegan tíma eða veruleg vanlíðan kallar á endurmat. Stækkun fyrir kynþroska, óeðlilegur þroski, grunsamlegur hnútur eða almenn einkenni ætti að rannsaka fyrr. Túlka verður niðurstöður hormónamælinga með hliðsjón af aldri og kynþroskastigi, en ekki eingöngu út frá viðmiðunarmörkum fullorðinna.
Geta eðlilegar hormónaprófanir útilokað brjóstakrabbamein eða eistnakrabbamein?
Normal hormone tests cannot rule out breast or testicular cancer. Both hCG and AFP can be normal in a person with a testicular mass, and breast cancer may occur without abnormal testosterone or estradiol. A new hard breast lump, nipple change or testicular lump therefore needs examination and appropriate imaging regardless of the laboratory panel. Sudden severe testicular pain is an emergency and should not wait for a routine 3–6 month follow-up or laboratory appointment.
Fáðu útskýringar á niðurstöðum blóðrannsókna
Hladdu upp rannsóknarskýrslunni þinni og AI Kantesti útskýrir hvert lífmerki á mannamáli á nokkrum sekúndum. Yfir 2 milljónir manna um allan heim nota þjónustuna.
Heimildir
- Klein, T., Mitchell, S., & Weber, H. (2026). Leiðarvísir um járnrannsóknir: TIBC, járnmettun og járnbindigeta. Kantesti AI Medical Research. DOI
- Klein, T., Mitchell, S., & Weber, H. (2026). aPTT-viðmiðunarmörk: leiðarvísir um D-dímer og prótein C í blóðstorknun. Kantesti AI Medical Research. DOI
- Kanakis GA et al. (2019). EAA clinical practice guidelines—gynecomastia evaluation and management. Andrology. DOI
- Bhasin S et al. (2018). Testosterone Therapy in Men With Hypogonadism: An Endocrine Society Clinical Practice Guideline. The Journal of Clinical Endocrinology & Metabolism. DOI PubMed
- 2M+Greindar rannsóknir
- 127+Lönd
- 100+Tungumál
Um læknateymið
E-E-A-T traustmerki
Reynsla
Læknastýrð klínísk yfirferð á vinnuferlum við túlkun rannsóknarniðurstaðna.
Sérþekking
Áhersla á rannsóknarstofulækningar: hvernig lífmarkarar hegða sér í klínísku samhengi.
Yfirvald
Dr. Thomas Klein fór yfir efnið læknisfræðilega, með framlagi frá Dr. Sarah Mitchell og Prof. Dr. Hans Weber.
Traustleiki
Rökstudd túlkun byggð á gögnum með skýrum eftirfylgnileiðum til að draga úr ávörun.
Fyrirvari um læknisfræðilegt efni
Þessi grein er eingöngu til fræðslu og felur ekki í sér læknisráðgjöf. Leitaðu alltaf til hæfs heilbrigðisstarfsmanns vegna ákvarðana um greiningu og meðferð.
Gefið út · Hafðu samband við ritstjórnarteymið
Gefið út af Kantesti Ltd, skráðu í Englandi og Wales, fyrirtækisnúmer. 17090423, London, Bretlandi.
